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CONGENITAL HEART DISEASE
Acute endothelin A receptor antagonism improves
pulmonary and systemic haemodynamics in patients with
pulmonary arterial hypertension that is primary or
autoimmune and related to congenital heart disease
S C Apostolopoulou, S Rammos, Z S Kyriakides, D J Webb, N R Johnston,
D V Cokkinos, D Th Kremastinos
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Heart 2003;89:1221–1227
Objective: To evaluate the acute haemodynamic effect of BQ-123, a selective endothelin A receptor
antagonist, in severe chronic pulmonary arterial hypertension (PAH) of primary or autoimmune origin
or related to congenital heart disease.
Design: Prospective open clinical study.
Setting: Cardiology tertiary referral centre.
Patients: 26 patients with chronic PAH were studied, with mean (SEM) age 29 (3) years (range 4–71
years), mean pulmonary artery pressure 68 (4) mm Hg, and pulmonary vascular resistance index
1694 (170) dyne.s.cm−5. Patients were divided in three groups according to PAH aetiology: primary or
autoimmune PAH (n = 12), and PAH associated with congenital heart defects with (n = 6) or without
(n = 8) complete mixing.
Intervention: BQ-123 200 nmol/min was infused for 60 minutes in the right atrium with sequential
haemodynamic measurements at 30 minute intervals.
Results: BQ-123 improved mean pulmonary artery pressure from 68 (4) to 64 (4) mm Hg (p < 0.05),
pulmonary vascular resistance index from 1694 (170) to 1378 (145) dyne.s.cm−5 (p < 0.001), pulmo-
nary cardiac index from 3.0 (0.2) to 3.4 (0.3) l/min/m2 (p < 0.001), and effective cardiac index from
2.5 (0.2) to 2.7 (0.2) l/min/m2 (p < 0.01). Haemodynamic response was similar in all groups except
for systemic cardiac index where a different (p = 0.0001, F = 5.53) response was observed; systemic
cardiac index increased from 2.7 (0.2) to 2.9 (0.2) l/min/m2 (p < 0.001) when patients with complete
mixing were excluded, in whom systemic cardiac index tended to decrease from 3.4 (1.0) to 3.0
(0.6) l/min/m2 (p = 0.06).
Conclusions: Acute endothelin A receptor antagonism induces substantial haemodynamic
improvement in severe chronic PAH of primary or autoimmune origin or related to congenital heart dis-
ease.
Pulmonary arterial hypertension (PAH) is a rare diseasewith diverse pathophysiological mechanisms, an oftenchallenging management, and a poor prognosis. The
overall one year survival from diagnosis for patients with pri-
mary PAH who do not respond to vasodilatators, such as cal-
cium channel blockers or epoprostenol, is 60–70%,1 while
responders to vasodilatators have better survival.2 Indices of
right heart failure, such as increased right atrial pressure and
decreased cardiac index, are associated with reduced survival,
both in the adult2 and in the paediatric populations.3 Irrevers-
ible PAH results from vascular remodelling with narrowing
and obliteration of pulmonary arteries, but the molecular
mechanisms underlying this process are unknown. Endothe-
lin (ET) 1 is an endothelium derived peptide, which exerts
profound vasoconstriction through action on ETA and ETB
receptors on smooth muscle cells and vasodilatation through
action on ETB receptors on endothelium, leading to prostacyc-
lin and nitric oxide release.4 Patients with PAH may have
increased plasma ET-1 concentrations5 and greatly increased
ET-1 expression in vascular endothelial cells of the pulmonary
bed.6 Endothelin converting enzyme inhibition7 and endothe-
lin receptor antagonism (ERA)8 protect from the development
of PAH or ameliorate existing PAH in animal models.9 More
recent human studies with ERA show improvement in
pulmonary and systemic haemodynamics in patients with
heart failure10 and infants with PAH after congenital heart
surgery in a small study, which also reported potentially
adverse effects from ERA use in the acute postoperative
period.11 ERA with the dual receptor antagonist bosentan has
been shown to be beneficial in patients with primary or auto-
immune PAH, both acutely in a small study12 and chronically
in a larger study in which ERA improved exercise capacity,
dyspnoea index, and functional class, while increasing the
time to clinical worsening.13 A recent study14 showed improve-
ment in cardiopulmonary haemodynamics and exercise
capacity with the ETA receptor antagonist sitaxsentan in a
mixed PAH population without separate analysis of haemody-
namic response in the various subgroups.
The purpose of this study was to evaluate the effect of con-
tinuous short term ETA receptor antagonism on the haemody-
namic condition of patients with severe chronic PAH of diverse
aetiology: primary, autoimmune, and PAH related to congeni-
tal heart disease, with emphasis on detailed analysis of the
haemodynamic response depending on the presence and
degree of pulmonary and systemic circulation mixing.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: ERA, endothelin receptor antagonism; ET, endothelin;
PAH, pulmonary arterial hypertension
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Twenty six patients (11 male and 15 female patients) with
severe chronic PAH were enrolled in this study between May
1998 and May 2000 at our institution. Table 1 describes the
patients’ baseline clinical characteristics. In a predetermined
way, for the purpose of later analysis, the patients were divided
in three groups: group 1, with primary or autoimmune PAH
(n = 12); group 2, with PAH associated with congenital heart
disease without complete mixing (n = 8); and group 3, with
PAH associated with uncorrected congenital heart disease
with complete mixing, as in Eisenmenger syndrome (n = 6).
Mean (SEM) age at study was 29 (3) years (range 4–71 years,
median 28 years). Patients 13 and 14 had atrial shunts and
patients 21–26 had complete mixing lesions with unrestrictive
communications between the systemic and pulmonary circu-
lation and increased pulmonary vascular resistance that
precluded surgical correction.
All patients, excluding the preschool patients, underwent a
complete cardiopulmonary evaluation including physical
examination, ECG, chest radiograph, echocardiogram, lung
perfusion scan, and treadmill exercise stress test (Dargie pro-
tocol).
Study protocol
The study protocol was approved by the institutional review
committee and was conducted according to institutional
guidelines after written informed consent was obtained. Car-
diac catheterisation was performed under local anaesthesia
with additional intravenous midazolam for the four younger
patients. Pulmonary arterial, right atrial, and pulmonary cap-
illary wedge pressures were recorded with an end hole balloon
catheter (Swan-Ganz catheter) and systemic pressures were
obtained with a pigtail catheter. Systemic and pulmonary
arterial and venous saturations were obtained to calculate
cardiac outputs with the Fick principle using table derived
assumed oxygen consumption values.15 The transpulmonary
pressure gradient was defined as the difference between mean
pulmonary artery and mean pulmonary capillary wedge or
left atrial pressures. Pulmonary and systemic vascular
resistance indices were calculated by the standard formula.16
In no case was carbon dioxide raised above 42 mm Hg, thus
contributing to the increased pulmonary artery pressure or
resistance. During baseline evaluation, blood samples for ET-1
and BQ-123 measurements were obtained from the right
atrium, pulmonary artery, and aorta and stored at −70°C after
rapid centrifugation until assay.
All patients underwent continuous infusion of the highly
selective ETA antagonist BQ-123 (cyclo(-D-asp-L-pro-d = val-L-
leu-D-trp-), Clinalfa, Läufelfingen, Switzerland) for 60 min-
utes in the right atrium. Adult patients received 200 nmol/min
and paediatric patients received 100 nmol/min/m2, based on
previous studies.11 The above dose was selected because it has
been proved to be truly selective for the ETA receptor.
17 Haemo-
dynamic evaluation and site sampling were repeated at 30 and
60 minutes of the infusion and 30 minutes after the end of the
infusion.
Plasma ET-1 concentrations were determined by standard
radioimmunoassay (Peninsula Laboratories Europe, St Hel-
ens, UK), as previously described.18 BQ-123 concentrations in
plasma were measured by high performance liquid chroma-
tography with fluorescence detection, as previously
described.17
The descriptive data are presented as the mean (SEM). Sta-
tistical analysis of the data was performed with repeated
measures analysis of variances, followed by post hoc analysis
with Tukey’s test; differences were considered significant for
p < 0.05.
RESULTS
Excluding the patients with uncorrected congenital heart dis-
ease, echocardiograms showed dilatation of the right atrium
and ventricle with end diastolic diameter 2.8–5.5 cm in the
parasternal short axis view. There was moderate to severe
Table 1 Clinical data
Patient Group Diagnosis Age (years) Sex Symptoms Medications NYHA
1 1 Primary PAH 46 M DOE Nifedipine, warfarin II
2 1 Primary PAH 24 F DOE Nifedipine, warfarin II
3 1 Primary PAH 32 F DOE Furosemide, captopril II
4 1 Primary PAH 27 F DOE Warfarin II
5 1 Primary PAH 39 F DOE Nifedipine II
6 1 Primary PAH 31 M DOE, leg oedema Nifedipine, warfarin, digoxin, furosemide IV
7 1 Primary PAH 35 F DOE, syncope Furosemide II
8 1 Primary PAH 26 M DOE Furosemide II
9 1 PAH, cold agglutinin syndrome 50 M DOE, syncope Nifedipine, warfarin, furosemide IV
10 1 PAH, CREST syndrome 71 M DOE Nifedipine, furosemide II
11 1 PAH, systemic lupus erythematosus 38 F DOE, leg oedema Warfarin, furosemide, solumedrol III
12 1 PAH, systemic lupus erythematosus 25 F DOE Warfarin, solumedrol, endoxan II
13 2 PAH, secundum ASD 27 F DOE, cyanosis Nifedipine, warfarin, digoxin III
14 2 PAH, secundum ASD 32 F DOE, cyanosis Warfarin II
15 2 PAH, ASD repair at 7 years 17 F DOE, cyanosis Furosemide III





17 2 PAH, arterial switch at 2 weeks 8 M Mild DOE None II
18 2 PAH, PDA closure at 6 years 17 F DOE, chest pain Nifedipine, warfarin III
19 2 PAH, PDA closure at 15 years 46 F DOE, chest pain Nifedipine, warfarin IV
20 2 PAH, ASD repair at 45 years 46 M DOE, oedema Nifedipine, warfarin, digoxin, furosemide III
21 3 PAH, double inlet single left ventricle 12 F DOE, cyanosis None II
22 3 PAH, double inlet single left ventricle 5 F DOE, cyanosis Furosemide, digoxin, captopril II
23 3 PAH, double outlet right ventricle 39 M DOE, cyanosis Furosemide, aspirin II
24 3 PAH, truncus arteriosus, restrictive ASD 4 M DOE, cyanosis Digoxin, furosemide II
25 3 PAH, aortopulmonary window 29 F DOE None II
26 3 PAH, aortopulmonary window 12 M DOE, cyanosis None II
Group 1: primary or automimmune pulmonary arterial hypertension (PAH); group 2: PAH associated with congenital heart disease without complete
mixing; group 3: PAH associated with congenital heart disease with complete mixing.
ASD, atrial septal defect; CREST syndrome: calcinosis, Raynaud’s phenomenon, oesophageal dysmotility, sclerodactyly, and telangiectasias; DOE,
dyspnoea on exertion; F, female; M, male; NYHA, New York Heart Association functional class; PAH, pulmonary arterial hypertension; PDA, patent
ductus arteriosus; VSD, ventricular septal defect.
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right ventricular dysfunction with preserved left ventricular
function, mild to moderate pulmonary insufficiency, and
moderate to severe tricuspid regurgitation with maximal
velocities consistent with the invasively measured systolic
right ventricular pressure at a mean (SEM) of 103 (5) mm Hg.
Exercise capacity was limited in all tested patients with maxi-
mal oxygen consumption at 15.9 (1.4) ml/kg/min (Weber class
B to D). No patient had lung perfusion scan findings sugges-
tive of thromboembolic disease.
Mean (SEM) pulmonary artery pressure in the total cohort
at baseline was 68 (4) mm Hg (range 38–105 mm Hg),
pulmonary vascular resistance index was 1694 (170) dy-
ne.s.cm−5 (range 576–3968 dyne.s.cm−5), systemic vascular
resistance index was 2481 (171) dyne.s.cm−5 (range 1216–
4800 dyne.s.cm−5), and systemic cardiac index was 2.9 (0.2) l/
min/m2 (range 1.1–5.1 l/min/m2). No adverse effects were
noted.
Figure 1 shows in absolute values the effect of BQ-123 on
haemodynamic parameters in the total cohort (n = 26). We
observed significant decreases in mean pulmonary artery
pressure by 6 (2)%, pulmonary vascular resistance index by 19
(2)%, and right atrial pressure by 18 (5)%. There were signifi-
cant increases in the pulmonary cardiac index by 15 (3)% and
effective cardiac index by 10 (3)%. Transpulmonary pressure
gradient decreased by 8 (2)%, from 56 to 52 mm Hg
(p = 0.01). A marginal, not significant, decrease by 8 (3)%,
from 0.68 to 0.63, in the pulmonary to systemic vascular
resistance ratio was noted. There was a significant, but within
normal limits for the patients’ ages, decrease in systemic vas-
cular resistance by 10 (2)% without a decrease in mean arte-
rial pressure. The systemic cardiac index tended to increase by
8 (3)% without reaching significance.
The patients in group 1 with primary or autoimmune PAH
(n = 12) responded similarly to the total cohort with signifi-
cant (p < 0.001) improvement in mean pulmonary artery
pressure by 10 (2)%, from 54 to 49 mm Hg, pulmonary vascu-
lar resistance index by 20 (3)%, from 1565 to 1239 dyne.s.cm−5,
right atrial pressure by 23 (6)%, from 10 to 8 mm Hg, and
transpulmonary pressure gradient by 12 (2)%, from 44 to
39 mm Hg. In contrast with the total cohort, in group 1 the
systemic cardiac index increased by 12 (4)%, from 2.6 to 2.9 l/
min/m2 (p < 0.05). Systemic vascular resistance index de-
creased, while remaining within normal limits, by 7 (2)%,
from 2661 to 2234 dyne.s.cm−5 with stable mean arterial pres-
sure.
The patients in group 2 with PAH caused by congenital
heart disease without complete mixing (n = 8) responded
with significant (p < 0.05) improvement in pulmonary
Figure 1 Haemodynamic effects
over time of BQ-123 administration in
the total patient cohort. The three
groups responded similarly in all
haemodynamic variables except for
the systemic cardiac index. Numbers
in parentheses indicate mean values.
mAoP, mean aortic pressure; mPAP,
mean pulmonary artery pressure; NS,
non-significant; PVRI, pulmonary
vascular resistance index; Qeff,
effective cardiac index; Qp,
pulmonary cardiac index; Qs,
systemic cardiac index; RAP, right
atrial pressure; SVRI, systemic
vascular resistance index. *p < 0.05
v baseline; **p < 0.01 v baseline;
***p < 0.001 v baseline.
ETA antagonism improves pulmonary arterial hypertension 1223
www.heartjnl.com
vascular resistance index by 12 (4)%, from 1976 to 1734 dy-
ne.s.cm−5, pulmonary cardiac index by 18 (7)%, from 2.6 to
3.1 l/min/m2, and effective cardiac index by 14 (5)%, from 2.6
to 3.0 l/min/m2. In contrast with the total cohort but in agree-
ment with group 1, in group 2 the systemic cardiac index
increased by 14 (5)%, from 2.8 to 3.3 l/min/m2 (p < 0.05). Sys-
temic vascular resistance index decreased, while remaining
within normal limits, by 14 (3)%, from 2379 to 2033 dy-
ne.s.cm−5, with stable transpulmonary pressure gradient, mean
pulmonary artery, mean arterial, and right atrial pressure.
The patients in group 3 with PAH caused by congenital heart
disease with complete mixing or Eisenmenger syndrome
(n = 6) responded with significant (p < 0.05) improvement in
mean pulmonary artery pressure by 10 (3)%, from 89 to
78 mm Hg, pulmonary vascular resistance index by 24 (5)%,
from 1577 to 1184 dyne.s.cm−5, transpulmonary pressure
gradient by 11 (4)%, from 72 to 64 mm Hg, and pulmonary
vascular resistance ratio by 26 (4)%, from 0.73 to 0.74. Pulmo-
nary and effective cardiac index, right atrial and mean arterial
pressures, and systemic vascular resistance did not change sig-
nificantly. In contrast with groups 1 and 2, in group 3 the sys-
temic cardiac index tended to decrease by 10 (5)%, from 3.4 to
3.0 l/min/m2 (p = 0.06). Table 2 shows the individual haemo-
dynamic and aortic saturation responses at 60 minutes of
BQ-123 infusion in the patients with complete mixing.
As noted above, the main variation in the effect of BQ-123
infusion between the three groups concerned the systemic
cardiac index, where a different (p = 0.0001, F = 5.53)
response was observed (fig 2).
We also analysed the haemodynamic response excluding
the complete mixing lesions, therefore the capability for unre-
strictive right to left shunt. In four patients (15, 16, 19, and
20), no haemodynamic changes were observed with BQ-123
infusion. In the five responders (2, 5, 7, 10, and 12 in group 1)
with normal baseline systemic cardiac index at a mean (SEM)
of 3.4 (0.3) l/min/m2, mean pulmonary artery pressure
decreased by 13 (4)%, from 49 (8) to 42 (7) mm Hg, and pul-
monary vascular resistance by 16 (6)%, from 901 (274) to 762
(266) dyne.s.cm−-5, without a change in their systemic cardiac
index. The remaining 11 responders with decreased baseline
systemic cardiac index at 2.5 (0.9) l/min/m2 improved their
systemic cardiac index by 21 (11)%, to 3.0 (1.0) l/min/m2, and
their pulmonary vascular resistance by 21 (10)%, from 2006
(901) to 1580 (761) dyne.s.cm−5, without a significant decrease
of pulmonary artery pressure.
At baseline in the right atrium, plasma ET-1 concentrations
were a mean (SEM) of 3.9 (0.3) ng/l, with a range of
1.9–6.4 ng/l (normal range 1.0–4.5 ng/l). No significant differ-
ences between the various sites sampled or changes during
BQ-123 infusion were noted. The baseline pulmonary artery to
aorta ET-1 ratio was mostly over unity, decreasing significantly
after 60 minutes of BQ-123 infusion in the total cohort. This
tendency persisted when the patients with complete mixing
were excluded (fig 3).
The plasma BQ-123 concentrations in the pulmonary artery
increased from 0 at baseline to a mean (SEM) of 250







(dyne.s.cm−5) PVRI/SVRI ratio Qp (l/min/m2) Qs (l/min/m2)
0 min 60 min 0 min 60 min 0 min 60 min 0 min 60 min 0 min 60 min 0 min 60 min
21 70 75 92 83 1824 1344 0.8 0.6 3.7 4.6 3.1 2.6
22 80 86 71 59 704 472 0.6 0.4 6.3 7.6 5.1 3.8
23 84 86 90 90 1864 1552 0.4 0.3 2.8 3.4 2.1 2.0
24 88 88 74 68 672 648 0.5 0.4 6.2 5.8 3.8 3.4
25 95 95 95 91 1888 1168 0.7 0.5 3.6 5.5 2.7 3.0
26 95 95 99 77 2512 1920 1.3 1.0 3.0 3.0 3.7 3.1
Mean (SEM) 85 (4) 87 (3) 87 (5) 78 (5)** 1577 (300) 1184 (223)** 0.7 (0.1) 0.5 (0.1)** 4.3 (0.6) 5.0 (0.7) 3.4 (0.4) 3.0 (0.3)
**p<0.01 v baseline.
mPAP, mean pulmonary artery pressure; PVRI, pulmonary vascular resistance index; Qp, pulmonary cardiac index; Qs, systemic cardiac index; SVRI,
systemic vascular resistance index.
Figure 2 Haemodynamic effect over time of BQ-123
administration on the systemic cardiac index, showing differential
effects in the three studied groups.*p<0.05 v baseline.
Figure 3 Effect over time of BQ-123 administration on pulmonary
to aorta (PA/Ao) endothelin 1 (ET-1) concentration ratio in the total
cohort, as well as with the exclusion of patients with complete
mixing. *p < 0.05 v baseline.
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(40) nmol at 30 minutes and 236 (51) nmol at 60 minutes of
the infusion, decreasing sharply to 67 (40) nmol 30 minutes
after the end of the infusion.
DISCUSSION
Our data show that short term continuous intravenous
infusion of BQ-123, a selective ETA receptor antagonist, in
patients with severe chronic PAH induced haemodynamic
improvement by decreasing pulmonary vascular resistance.
Excluding the complete mixing lesions, in patients with nor-
mal baseline cardiac index this fall in pulmonary vascular
resistance resulted in decreased pulmonary artery pressure,
while in patients with decreased baseline cardiac index it led
to an improved cardiac index, with or without decreased pul-
monary artery pressure. This effect is still important, since the
symptoms of severe PAH are partly related to right ventricular
failure and the resultant decreased cardiac index. BQ-123 also
reduced right atrial pressure and increased systemic cardiac
index in the patients with non-complete mixing, thus reflect-
ing the improved right ventricle haemodynamic variables.
Patients with complete mixing lesions and non-reactive
increased pulmonary vascular resistance (Eisenmenger syn-
drome) have a relatively preserved systemic cardiac index at
the expense of significant cyanosis. In these patients, a
decrease in pulmonary vascular resistance with increased pul-
monary cardiac index would be expected to induce a
decreased systemic cardiac index but a decreased right to left
shunting and improved aortic saturation. Aortic saturation
improved over 7% during BQ-123 infusion in patients 21 and
22, our two most cyanotic patients (table 2).
Interestingly, patients 13 and 14 with unoperated atrial
septal defects responded similarly to group 2 patients and not
to group 3 patients. The observed response may be explained
by the presence of an atrial level shunt without unrestrictive
communication between the systemic and pulmonary circula-
tion as in group 3 patients, where an increase in pulmonary
cardiac index would be associated with a decrease in systemic
cardiac index. It is also important to note that, at the end of
the study, the pulmonary vascular resistance and pulmonary
artery pressure values remained greatly abnormal in all tested
patients, despite the observed improvement.
Systemic hypotension with ERA has been reported in two
previously published studies in patients with PAH without left
heart failure, involving acute administration of high bosentan
doses in infants with critical postoperative congenital heart
disease11 and primary or autoimmune PAH.12 Chronic admin-
istration of lower bosentan doses in patients with PAH did not
induce systemic hypotension.13 Previous studies have shown
significant systemic effects only with BQ-123 doses
> 300 nmol/min.17 Systemic vascular resistance decreased
within normal limits in our study with stable arterial pressure,
possibly because of our patients’ stable clinical conditions and
the conservative doses administered (200 nmol/min). BQ-123
has a short half life and is rapidly removed from plasma.
Hence, a local right atrial infusion in our study may well have
maximised delivery to the lung and explains the significant
improvement observed in pulmonary haemodynamics.
Previous studies of patients with PAH have reported ET-1
concentrations either higher than those in control subjects,
but within normal range19 or increased without haemody-
namic correlations and further increased after administration
of a dual ETA/ETB antagonist such as bosentan.
12 We found
relatively high baseline ET-1 concentrations that did not
correlate with haemodynamic parameters or change signifi-
cantly with BQ-123 infusion. This finding may result from the
short period of administration and the absence of interference
with ETB receptors, which have a role in ET-1 clearance.
20
Administration of sitaxsentan, another ETA receptor antago-
nist, actually decreased plasma ET-1 concentrations, possibly
because of the improved haemodynamics or more available
displaced ET-1 for clearance by ETB receptors.
21 Studies of PAH
patients without left heart failure have reported pulmonary to
arterial ET-1 ratios both below19 and close to unity.5 The
pulmonary to arterial ET-1 ratio over unity observed in this
study and its decrease with ERA has been reported before12
and may be caused by displacement of ET-1 from binding sites
in the lung.
ERA studies of patients with complete mixing lesions and
non-reactive increased pulmonary vascular resistance (Eisen-
menger syndrome) have not reported detailed haemodynamic
data. The only previous study with ETA receptor antagonism
over 12 weeks involving few patients with congenital heart
disease14 showed no short term effect or long term change in
cardiac output despite the improved pulmonary vascular
resistance, pulmonary artery pressure, and exercise capacity.
Both findings may be due to the heterogeneity of the popula-
tion and analysis of the data irrespective of the presence and
degree of mixing, which influences the ratio of pulmonary to
systemic cardiac output. Our patient population with com-
plete mixing was limited; however, acute ETA receptor antago-
nism in these patients was more selective to the pulmonary
circulation. This was shown by the improved pulmonary to
systemic vascular resistance ratio, pulmonary and effective
cardiac index, and pulmonary vascular resistance, without
greater reduction in systemic vascular resistance, which would
lead to increased right to left shunting and cyanosis. Aortic
saturation tended to increase in the more cyanotic patients as
a result of the more favourable pulmonary haemodynamics.
Chronic prostacyclin treatment is associated with consider-
able inconvenience and morbidity22 but its clinical benefits are
independent of its short term pulmonary vasodilatator effect.
ERA may be similar in benefit, since in animal studies it has
been shown to prevent and reverse PAH and promote pulmo-
nary vascular remodelling.23 The acute effects of ERA were not
only maintained but were also more pronounced during pro-
longed treatment in the case of heart failure10 and were
sustained over 12 weeks in the case of primary or autoimmune
PAH.13 The same long term improvement may well be encoun-
tered with ETA receptor antagonism in chronic PAH of diverse
pathophysiology, as was shown in one previous study includ-
ing a few congenital heart disease patients.14 A chronic
improvement of 11–26% in pulmonary vascular resistance and
cardiac index, as encountered in our responders, may be
expected to reduce symptoms and benefit this population in
the long term; however, this assumption can only be proved
with further studies.
Study limitations
This study has the limitations of an acute evaluation without
long term data and the relatively small sample size of patients
with PAH of diverse aetiology. The wide age range may also
affect the underlying disease process and the response to ERA.
The study is based on calculated haemodynamic measure-
ments, the validity of which may be influenced by factors such
as use of assumed oxygen consumption values. Like other
studies in this field of work, ours did not compare the effect of
ETA receptor antagonism with that of other vasoactive agents.
Such comparisons have been published in animal models
showing that ERA produces more potent pulmonary vasodila-
tation than nitric oxide inhalation alone, better endothelium
dependent vasodilatation, and increased pulmonary vascular
smooth muscle sensitivity to nitric oxide.24 In a small study of
acute PAH involving sequential 60 minute administration of
BQ-123 and prostacyclin, we have reported that patients
responded differently to each drug, possibly because of the
diverse pathophysiology of PAH and the different mechanisms
of action of the two agents.25 Against these limitations, this is
a study with detailed haemodynamic analysis of the effect of
selective ETA receptor antagonism in diverse aetiology PAH
that, importantly, involves less studied populations, such as
patients with congenital heart disease.
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Conclusion
This study showed that acute ETA receptor antagonism
induces haemodynamic improvement in patients with severe
chronic PAH that is primary or autoimmune, as well as PAH
related to congenital heart defects with or without complete
mixing. Additional detailed studies with long term ERA, espe-
cially in more poorly studied groups such as those with
congenital heart disease, are needed to determine whether the
observed effects are sustained and whether chronic oral ERA
may have a role in the treatment of PAH of diverse aetiology.
. . . . . . . . . . . . . . . . . . . . .
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